Patient-driven clinical trial offers new hope for rare cancer diagnosis
Marking World Cancer Day on 4 February, this special Monday Lunch Live event highlights new research into rare cancers – which collectively cause more cancer deaths in Australia than any single cancer type.
An innovative patient-driven clinical trial is exploring genomic profiling of rare cancers. The NOMINATOR trial is the result of a unique collaboration between a clinician-scientist and patient advocate. The trial investigates whether profiling can improve diagnosis and treatment of people with rare cancers.
Reflecting the I Am and I Will theme of World Cancer Day, Professor Clare Scott – clinician-scientist from the Walter and Eliza Hall Institute and medical oncologist at Peter MacCallum Cancer Centre; the Royal Women’s Hospital and Royal Melbourne Hospital – will be joined by Kate Vines, Founder and Head of Patient Care at Rare Cancers Australia. They will share their story of collaboration and commitment in developing the promising NOMINATOR trial.
Professor Clare Scott
Professor Clare Scott holds the Chair in Gynaecological Cancer at the University of Melbourne and is the Joint-Head of Clinical Translation and Laboratory Head at the Walter and Eliza Hall Institute and Medical Oncologist at the Peter MacCallum Cancer Centre, Royal Women’s and Royal Melbourne Hospitals.
She has 20 years’ experience in clinical cancer genetics, including working in Familial Cancer Clinics. Her clinical expertise is in gynaecological cancers and coordinating care for patients with rare cancers. Her laboratory focuses on drug resistance in ovarian cancer and other rare cancer subtypes, generating patient-specific models to understand and avert resistance to targeted therapeutics, in particular, PARP inhibitors.
Professor Scott chairs the COSA Rare Cancer group and has been awarded clinical fellowships from the Victorian Cancer Agency (2011, 2017), the Sir Edward Dunlop Cancer Research Fellow from the Cancer Council Victoria (2012) and the Jeannie Ferris Recognition Award in Gynaecological Cancer from Cancer Australia (2018).
Kate Vines is the Founder and Head of Patient Care for Rare Cancers. In 2012 Kate and her husband Richard established Rare Cancers Australia, a patient advocacy group whose mission is to improve the lives and outcomes for rare cancer patients.
The event will also feature a patient experience perspective of the NOMINATOR trial.
Monday 4 February 2019
VCCC Building, Level 7 Lecture Theatres
Light lunch served from 12.30pm
Presentation from 1-2pm
Can’t join us in person? Join us online via our Webinar
The article is courtesy of our proud precinct partner, the Victorian Comprehensive Cancer Centre